| scholarly article | Q13442814 |
| P50 | author | Kiat Ruxrungtham | Q66733145 |
| Somnuek Sungkanuparph | Q75156091 | ||
| P2093 | author name string | Weerawat Manosuthi | |
| Sirirat Likanonsakul | |||
| Aroon Lueangniyomkul | |||
| Supeda Thongyen | |||
| Preecha Tantanathip | |||
| Wiroj Mankatitham | |||
| N2R Study Team | |||
| Sunantha Burapatarawong | |||
| Unchana Thawornwa | |||
| Vilaiwan Prommool | |||
| Wisit Prasithsirskul | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rifampicin | Q422652 |
| randomized experiment | Q1231081 | ||
| P304 | page(s) | 1752-1759 | |
| P577 | publication date | 2009-06-01 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study | |
| P2283 | uses | randomized experiment | Q1231081 |
| P478 | volume | 48 |
| Q34134900 | 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis |
| Q36263781 | A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study |
| Q46662118 | ART and tuberculosis: the final nail in nevirapine's coffin? |
| Q40051462 | Addressing Antiretroviral Therapy-Associated Drug-Drug Interactions in Patients Requiring Treatment for Opportunistic Infections in Low-Income and Resource-Limited Settings. |
| Q35770848 | Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to? |
| Q26829101 | Antituberculosis therapy for 2012 and beyond |
| Q37845854 | Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients |
| Q37108384 | Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. |
| Q37392789 | Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin |
| Q33623024 | CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1 |
| Q37002481 | Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults |
| Q36031230 | Comparative effectiveness of efavirenz-based antiretroviral regimens in resource-limited settings |
| Q64899470 | Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis. |
| Q38961883 | Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis |
| Q24609011 | Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all |
| Q37809112 | Drug–drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition |
| Q30240127 | Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals |
| Q24235724 | Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals |
| Q33809438 | Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults |
| Q37757660 | Global tuberculosis drug development pipeline: the need and the reality. |
| Q35530299 | Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand |
| Q30052157 | HIV and Tuberculosis: a Deadly Human Syndemic |
| Q37103666 | Human immunodeficiency virus-associated tuberculosis: update on prevention and treatment |
| Q33686938 | Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand |
| Q36558327 | Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients |
| Q34756398 | Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study |
| Q35043048 | Initiating antiretrovirals during tuberculosis treatment: a drug safety review |
| Q26749428 | Integrated therapy for HIV and tuberculosis |
| Q37690861 | Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients |
| Q42251901 | Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism |
| Q37666456 | Management of individuals requiring antiretroviral therapy and TB treatment |
| Q28555028 | Might ART Adherence Estimates Be Improved by Combining Biomarker and Self-Report Data? |
| Q34710641 | Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship |
| Q59650851 | Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial |
| Q37369594 | Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study |
| Q47102399 | Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study |
| Q30578338 | New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data |
| Q27021762 | Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis |
| Q35102702 | Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection |
| Q52330065 | Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review. |
| Q36410952 | Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations |
| Q35114865 | Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial) |
| Q24602072 | Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients |
| Q34488494 | Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens |
| Q37153012 | Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers |
| Q91822580 | Switching protease inhibitors to rilpivirine in HIV-positive individuals with complete viral suppression and without prior HIV drug resistance in a resource-limited setting: a randomized controlled trial |
| Q36099838 | TB and HIV Therapeutics: Pharmacology Research Priorities |
| Q40867178 | Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial |
| Q34252288 | The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study |
| Q34475542 | Timing of antiretroviral therapy for HIV in the setting of TB treatment |
| Q38207924 | Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins |
| Q35477959 | Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. |
| Q37895251 | Tuberculosis and HIV co-infection: screening and treatment strategies |
| Q34547644 | Tuberculosis as part of the natural history of HIV infection in developing countries |
| Q30411703 | Understanding pharmacokinetics to improve tuberculosis treatment outcome |
Search more.